Eluvia™ Drug-Eluting Stent

The Standard.
By every Measure.

Data from the patients you actually treat.

Across meta-analyses, head-to-head RCTs and real-world studies, Eluvia's outcomes hold up study after study. As new data is released, you'll find it here: another study, another reason Eluvia is THE STANDARD.

Check out more real-world evidence at...
TCT | VEITH | PVI

What is the ELEGANCE Registry?

ELEGANCE — Drug-ELuting REGistry: ReAl world TreameNt of Lesions in the Peripheral VasCularturE — is a global, prospective, post-market registry generating real-world evidence for Boston Scientific drug-eluting technologies in the treatment of perpherial arterial disease.

It is the largest prospective global registry ever performed in PAD, and the largest prospective registry of women and underrepresented minorities with PAD — populations historically underrepresented in clinical studies, and the patients physicians see every day.

Randomized trials show what a device can do. Real-world evidence shows what it does for the patients in front of you.

Post-market Registry

Non-randomized, prospective, global multi-center

Diverse Enrollment Objective

≥40% women - ≥40% underrepresented minorities

Treatment Target

Lesions in the peripheral arterial circulation, treated iwth Eluvia DES and/or Ranger DCB

Evaluation & Follow-up

Per site and treating-physician standard of care

12-Month Data Set
1-Year Female Cohort Subset

ELEGANCE Registry 12 Month Data Set¹

Released Oct 6^th, 2026

ELEGANCE Registry. Patients treated with Eluvia showed consistently positive 12-month outcomes.

ELEGANCE Registry. 12-month freedom from CD-TLR.

ELEGANCE Registry. 12-month freedom from major amputation.

ELEGANCE Registry. Post Market Regsitry: Non-randomized, prospective, global, multi-center. Diverse enrollment objective: greater than 40% women, greater than 40% URM. Treatment target: lesions in peripheral arterial circulation. Evaluation & follow-up: per site and treating physician standard of care.

ELEGANCE Registry Page 1
ELEGANCE Registry Page 2
ELEGANCE Registry Page 3
ELEGANCE Registry Page 4

Download the ELEGANCE 12-month sheet

ELEGANCE 1 Year Data – Female Cohort²

Released Nov 2^nd, 2026

The Standard. By every measure. Comparable clinical outcomes despite sex-based differences. 89.3 percent female 1-year primary patency (versus 91.3 percent male, NS).

The Standard. By every measure. Comparable clinical outcomes despite sex-based differences. 97.6 percent freedom from major amputation (versus 98.4 percent male, NS).

The Standard. By every measure. Comparable clinical outcomes despite sex-based differences. Plus 1.4 points female 1-year VascuQoL gain (versus plus 1.3 male, NS).

ELEGANCE Registry Female Cohort. Despite significant sex-based differences in clinical presentation and patient-reported procedural experiences, females achieved 1-year effectiveness and quality-of-life outcomes comparable to males. At baseline, females were: Significantly older (71.0 vs 68.9 yrs; P<0.0001). More often Rutherford 4–6 (44.0% vs 37.5%; P=0.0087). Less often married/partnered (37.9% vs 65.8%; P<0.0001) and more likely living alone. Lower baseline VascuQoL (3.6 vs 4.0; P=0.0385). Similar current diabetes (55.9% vs 59.0%; P=0.6752) and lesion length (148.5 vs 142.9mm; P=0.2123).

ELEGANCE 1 Year Data Page 1
ELEGANCE 1 Year Data Page 2
ELEGANCE 1 Year Data Page 3
ELEGANCE 1 Year Data Page 4

TRUE-PTX Eluvia Subgroup Analysis³

Before matching

12-month amputations occurred less frequently for patients treated with Eluvia DES

	Eluvia	non-DE	P-value
Any Limb Amputation	7.7%	8.9%	0.265
Same Limb Amputation	1.9%	2.3%	0.391
Any Readmission	51.9%	57.8%	0.001

After Matching⁴

Patients treated with non-DE devices were more likely to have any above-ankle amputation and any readmission compared with Eluvia DES

Treatment with a non-DE device increased odds for any above-ankle amputation by

47%

Treatment with a non-DE device increased odds for any readmission by

23%

Learn more about the standard

Drug Elution case library

See how physicians are using drug-eluting technologies in real-world practice.

View case studies

Contact us

Connect with an Eluvia representative to learn more about the standard for SFA stenting.

Reach out today

Full drug elution portfolio

Explore our comprehensive range of drug-eluting technologies designed to improve patient outcomes.

Explore more

Eluvia indications, safety, and warnings

Ranger indications, safety, and warnings

References:

1. Secemsky E, on behalf of the ELEGANCE Investigators. 12-month Outcomes for Patients with Complex PAD Treated with Eluvia DES from the ELEGANCE Registry. VIVA 2026 Scientific Sessions, Las Vegas, NV; 2026.
2. TCT 2026 ELEGANCE female abstract (15-Jun-2026) & ELEGANCE Female Focus Analysis Statistical Report.
3. Brian DeRubertis. Polymer-based Drug-Eluting Stent vs Bare Device Therapies for PAD In the Real World: 12-Month Amputation and Readmission Rates in a Large Nationwide Population. Presented at CX 23 April 2025.
4. Exact Matching Method.

My account

The Standard. By every Measure.

Check out more real-world evidence at... TCT | VEITH | PVI